Clinical Trial Update: A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy. [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating weekly 40,000 units of epoetin alfa (PROCRIT) in cancer patients with anemia who are not receiving chemotherapy was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia
• Cancer

Drugs mentioned

• PROCRIT (epoetin alfa) (epoetin alfa)

Snippet

Sponsor: Ortho Biotech Products, L.P. | Conditions: Anemia, Neoplasms | Phase 3 | Status: TERMINATED